phase I clinical study
Tempus, Actuate Therapeutics Ink Collaboration to Discover Biomarkers of Response for Elraglusib
Tempus will provide its clinical xF+ liquid biopsy and research-use-only DNA methylation tests to the ongoing Phase I/II trial of Actuate's GSK-3β inhibitor elraglusib.
The consumer genetics firm will soon be able to team with other drug companies as it mines its genotypic database for new disease pathways.
Caris Life Sciences, Essa Pharma Ink Liquid Biopsy Partnership for Prostate Cancer Trial
Essa will use Caris' blood-based sequencing tests to assess the genetic profiles of mCRPC patients enrolled in a Phase I trial of the firm's investigational agent.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.